GB9601666D0
(en)
*
|
1996-01-27 |
1996-03-27 |
Zeneca Ltd |
Chemical compounds
|
GB9702213D0
(en)
|
1996-02-24 |
1997-03-26 |
Zeneca Ltd |
Chemical compounds
|
GB9609919D0
(en)
*
|
1996-05-11 |
1996-07-17 |
Zeneca Ltd |
Chemical compounds
|
GB9717804D0
(en)
|
1997-08-22 |
1997-10-29 |
Zeneca Ltd |
Chemical compounds
|
GB9717807D0
(en)
|
1997-08-22 |
1997-10-29 |
Zeneca Ltd |
Chemical compounds
|
AU764184B2
(en)
|
1998-01-23 |
2003-08-14 |
Pharmacia & Upjohn Company |
Oxazolidinone combinatorial libraries, compositions and methods of preparation
|
US7002020B1
(en)
|
1998-01-23 |
2006-02-21 |
Pharmacia & Upjohn Company |
Oxazolidinone combinatorial libraries, compositions and methods of preparation
|
US6562844B2
(en)
|
1998-01-23 |
2003-05-13 |
Pharmacia & Upjohn Company |
Oxazolidinone combinatorial libraries, compositions and methods of preparation
|
HUP0103082A3
(en)
|
1998-06-05 |
2002-12-28 |
Astrazeneca Ab |
Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
|
GB9928568D0
(en)
|
1999-12-03 |
2000-02-02 |
Zeneca Ltd |
Chemical compounds
|
DE19958153A1
(de)
*
|
1999-12-03 |
2001-06-07 |
Yamanouchi Pharma Co Ltd |
Oxazolidinon-Derivate
|
DE19962924A1
(de)
|
1999-12-24 |
2001-07-05 |
Bayer Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
GB0009803D0
(en)
|
2000-04-25 |
2000-06-07 |
Astrazeneca Ab |
Chemical compounds
|
WO2003008389A1
(en)
*
|
2001-07-16 |
2003-01-30 |
Ranbaxy Laboratories Limited |
Oxazolidinone derivatives as potential antimicrobials
|
PL363960A1
(en)
*
|
2000-07-17 |
2004-11-29 |
Ranbaxy Laboratories Limited |
Oxazolidinone derivatives as antimicrobials
|
MXPA03003473A
(es)
|
2000-10-17 |
2003-08-19 |
Upjohn Co |
Metodos para producir compuestos de oxazolidinona.
|
US7160912B2
(en)
*
|
2000-12-26 |
2007-01-09 |
Dr.Reddy's Laboratories Ltd. |
Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them
|
SE0100326D0
(sv)
|
2001-02-02 |
2001-02-02 |
Astrazeneca Ab |
New compounds
|
CA2405532A1
(en)
|
2001-02-07 |
2002-08-22 |
Ortho-Mcneil Pharmaceutical, Inc. |
Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods
|
EP1379509A1
(en)
*
|
2001-04-20 |
2004-01-14 |
PHARMACIA & UPJOHN COMPANY |
A method for the preparation of oxazolidinones
|
DE10129725A1
(de)
|
2001-06-20 |
2003-01-02 |
Bayer Ag |
Kombinationstherapie substituierter Oxazolidinone
|
US6956040B2
(en)
*
|
2001-07-16 |
2005-10-18 |
Ranbaxy Laboratories Limited |
Oxazolidinone piperazinyl derivatives as potential antimicrobials
|
KR20040106551A
(ko)
*
|
2002-05-15 |
2004-12-17 |
랜박시 래보러터리스 리미티드 |
페닐 옥사졸리디논 유도체의 다형 제제
|
EP1539745B1
(en)
|
2002-08-12 |
2006-03-29 |
Pharmacia & Upjohn Company LLC |
N-aryl-2-oxazolidinones and their derivatives
|
WO2004026848A1
(en)
|
2002-09-20 |
2004-04-01 |
Lupin Limited |
Oxazolidinone derivatives, process for their preperation and their use as antimycobacterial agents
|
ATE344036T1
(de)
*
|
2002-11-21 |
2006-11-15 |
Pharmacia & Upjohn Co Llc |
N-(4-(piperazin-1-yl)-phenyl-2-oxazolidinon-5- carbonsäureamid-derivate und verwandte verbindungen als antibakterielle mittel
|
DE10300111A1
(de)
|
2003-01-07 |
2004-07-15 |
Bayer Healthcare Ag |
Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
|
US7687627B2
(en)
*
|
2003-09-08 |
2010-03-30 |
Wockhardt Limited |
Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy
|
DE10355461A1
(de)
|
2003-11-27 |
2005-06-23 |
Bayer Healthcare Ag |
Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
|
US7715789B2
(en)
*
|
2005-01-20 |
2010-05-11 |
Song park |
Method and apparatus mechanically providing and/or using modulated audio effects into the interior of human flesh
|
EP1685841A1
(en)
|
2005-01-31 |
2006-08-02 |
Bayer Health Care Aktiengesellschaft |
Prevention and treatment of thromboembolic disorders
|
WO2007004049A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Pharmacia & Upjohn Company Llc |
Oxazolidinones containing azetidine as antibacterial agents
|
DE102005045518A1
(de)
|
2005-09-23 |
2007-03-29 |
Bayer Healthcare Ag |
2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
|
DE102005047561A1
(de)
|
2005-10-04 |
2007-04-05 |
Bayer Healthcare Ag |
Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
|
RU2429236C2
(ru)
|
2005-10-04 |
2011-09-20 |
Байер Шеринг Фарма Акциенгезельшафт |
Новая полиморфная форма и аморфная форма 5-хлор-n-({(5s)-2-оксо-3-[4-(3-оксо-4-морфолинил)-фенил]-1, 3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида
|
CA2647605A1
(en)
|
2006-03-31 |
2007-10-11 |
Research Foundation Itsuu Laboratory |
Novel compound having heterocyclic ring
|
CA2647597A1
(en)
|
2006-05-31 |
2007-12-06 |
Abbott Laboratories |
Thiazole compounds as cannabinoid receptor ligands and uses thereof
|
US7875639B2
(en)
|
2006-05-31 |
2011-01-25 |
Abbott Laboratories |
Compounds as cannabinoid receptor ligands and uses thereof
|
US8841334B2
(en)
|
2006-05-31 |
2014-09-23 |
Abbvie Inc. |
Compounds as cannabinoid receptor ligands and uses thereof
|
US8796267B2
(en)
|
2006-10-23 |
2014-08-05 |
Concert Pharmaceuticals, Inc. |
Oxazolidinone derivatives and methods of use
|
US20080139563A1
(en)
*
|
2006-10-23 |
2008-06-12 |
Concert Pharmaceuticals Inc. |
Oxazolidinone derivatives and methods of use
|
AU2008226947B2
(en)
|
2007-03-08 |
2014-07-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
|
EP2142522A1
(en)
|
2007-03-28 |
2010-01-13 |
Abbott Laboratories |
1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands
|
US7872033B2
(en)
|
2007-04-17 |
2011-01-18 |
Abbott Laboratories |
Compounds as cannabinoid receptor ligands
|
US8501794B2
(en)
|
2007-04-17 |
2013-08-06 |
Abbvie Inc. |
Compounds as cannabinoid receptor ligands
|
DE102007018662A1
(de)
|
2007-04-20 |
2008-10-23 |
Bayer Healthcare Ag |
Oxazolidinone zur Behandlung und Prophylaxe von pulmonaler Hypertonie
|
MX2009012374A
(es)
|
2007-05-18 |
2009-12-01 |
Abbott Lab |
Compuestos novedosos como ligandos del receptor de canabinoides.
|
DE102007028318A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Oxazolidinone zur Behandlung und Prophylaxe von Sepsis
|
CN101883768A
(zh)
|
2007-10-02 |
2010-11-10 |
财团法人乙卯研究所 |
具有7元杂环的噁唑烷酮衍生物
|
US9193713B2
(en)
|
2007-10-12 |
2015-11-24 |
Abbvie Inc. |
Compounds as cannabinoid receptor ligands
|
CA2716857A1
(en)
|
2008-03-11 |
2009-09-17 |
Teodozyi Kolasa |
Novel compounds as cannabinoid receptor ligands
|
MX2010010773A
(es)
|
2008-04-01 |
2011-04-11 |
Abbott Gmbh & Co Kg |
Tetrahidroisoquinolinas, composiciones farmaceuticas que las contienen y su uso en terapia.
|
WO2009154754A2
(en)
|
2008-06-17 |
2009-12-23 |
Concert Pharmaceuticals, Inc. |
Synthesis of deuterated morpholine derivatives
|
EP2138178A1
(en)
|
2008-06-28 |
2009-12-30 |
Bayer Schering Pharma Aktiengesellschaft |
Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
|
EP2140866A1
(en)
|
2008-07-04 |
2010-01-06 |
Bayer Schering Pharma Aktiengesellschaft |
Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract
|
JP2012500198A
(ja)
|
2008-08-15 |
2012-01-05 |
アボット・ラボラトリーズ |
カンナビノイド受容体リガンドとしてのイミン誘導体
|
US8846730B2
(en)
|
2008-09-08 |
2014-09-30 |
Abbvie Inc. |
Compounds as cannabinoid receptor ligands
|
WO2010028175A1
(en)
|
2008-09-08 |
2010-03-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulators of aldehyde dehydrogenase activity and methods of use thereof
|
TW201016692A
(en)
|
2008-09-16 |
2010-05-01 |
Abbott Lab |
Novel compounds as cannabinoid receptor ligands
|
CA2737768A1
(en)
|
2008-10-17 |
2010-04-22 |
Abbott Laboratories |
Trpv1 antagonists
|
JP2012505908A
(ja)
|
2008-10-17 |
2012-03-08 |
アボット・ラボラトリーズ |
Trpv1アンタゴニスト
|
KR20110082180A
(ko)
|
2008-10-28 |
2011-07-18 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
알데히드 탈수소효소의 조절자 및 그것의 사용방법
|
US8557983B2
(en)
|
2008-12-04 |
2013-10-15 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
UA108193C2
(uk)
|
2008-12-04 |
2015-04-10 |
|
Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
|
US20100160322A1
(en)
|
2008-12-04 |
2010-06-24 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US8586754B2
(en)
|
2008-12-05 |
2013-11-19 |
Abbvie Inc. |
BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
EP2376480B1
(en)
|
2008-12-05 |
2016-06-01 |
AbbVie Inc. |
Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
US8563735B2
(en)
|
2008-12-05 |
2013-10-22 |
Abbvie Inc. |
Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
PA8854001A1
(es)
|
2008-12-16 |
2010-07-27 |
Abbott Lab |
Compuestos novedosos como ligandos de receptores de canabinoides
|
RU2538965C2
(ru)
|
2009-01-19 |
2015-01-10 |
Эббви Инк. |
Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
|
MX2011007681A
(es)
|
2009-01-19 |
2011-08-08 |
Abbott Lab |
Agentes inducidores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes.
|
TW201038569A
(en)
|
2009-02-16 |
2010-11-01 |
Abbott Gmbh & Co Kg |
Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
|
AR075442A1
(es)
|
2009-02-16 |
2011-03-30 |
Abbott Gmbh & Co Kg |
Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
|
TWI519530B
(zh)
|
2009-02-20 |
2016-02-01 |
艾伯維德國有限及兩合公司 |
羰醯胺化合物及其作為鈣蛋白酶(calpain)抑制劑之用途
|
US8236822B2
(en)
|
2009-03-27 |
2012-08-07 |
Abbott Laboratories |
Compounds as cannabinoid receptor ligands
|
US8841296B2
(en)
*
|
2009-03-27 |
2014-09-23 |
Council of Scientific and Industrial Research, Anusandhan Bhawan, Rafi Marg |
Substituted 1, 4-dioxa-8-azaspiro[4,5]decanes useful as fungicides and a process for the preparation thereof
|
EP2411382A1
(en)
|
2009-03-27 |
2012-02-01 |
Abbott Laboratories |
Compounds as cannabinoid receptor ligands
|
US8288428B2
(en)
|
2009-03-27 |
2012-10-16 |
Abbott Laboratories |
Compounds as cannabinoid receptor ligands
|
US8507493B2
(en)
|
2009-04-20 |
2013-08-13 |
Abbvie Inc. |
Amide and amidine derivatives and uses thereof
|
US8236798B2
(en)
|
2009-05-07 |
2012-08-07 |
Abbott Gmbh & Co. Kg |
Carboxamide compounds and their use as calpain inhibitors
|
KR101920202B1
(ko)
|
2009-05-26 |
2018-11-21 |
애브비 아일랜드 언리미티드 컴퍼니 |
암,면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
|
US20220315555A1
(en)
|
2009-05-26 |
2022-10-06 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US8546399B2
(en)
|
2009-05-26 |
2013-10-01 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US9034875B2
(en)
|
2009-05-26 |
2015-05-19 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US8962639B2
(en)
|
2009-05-29 |
2015-02-24 |
Abbvie Inc. |
Potassium channel modulators
|
WO2011053740A1
(en)
|
2009-10-28 |
2011-05-05 |
Belkin International, Inc. |
Portable multi-media communication device protective carrier and method of manufacture therefor
|
CN102666495A
(zh)
|
2009-11-25 |
2012-09-12 |
雅培制药有限公司 |
钾通道调节剂
|
TW201130855A
(en)
|
2009-12-16 |
2011-09-16 |
Abbott Lab |
Prodrug compounds useful as cannabinoid ligands
|
PT2550258E
(pt)
|
2010-03-25 |
2015-11-30 |
Abbvie Inc |
Agentes indutores de apoptose para o tratamento de cancro e de doenças imunitárias e autoimunes
|
TWI520960B
(zh)
|
2010-05-26 |
2016-02-11 |
艾伯維有限公司 |
用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
|
US8586596B2
(en)
|
2010-06-15 |
2013-11-19 |
Abbvie Inc. |
Compounds as cannabinoid receptor ligands
|
KR20130097748A
(ko)
|
2010-08-10 |
2013-09-03 |
아비에 인코포레이티드 |
신규한 trpv3 조절제
|
US8877794B2
(en)
|
2010-08-13 |
2014-11-04 |
Abbott Laboratories |
Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US9045459B2
(en)
|
2010-08-13 |
2015-06-02 |
AbbVie Deutschland GmbH & Co. KG |
Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US8883839B2
(en)
|
2010-08-13 |
2014-11-11 |
Abbott Laboratories |
Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US9051280B2
(en)
|
2010-08-13 |
2015-06-09 |
AbbVie Deutschland GmbH & Co. KG |
Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US8846743B2
(en)
|
2010-08-13 |
2014-09-30 |
Abbott Laboratories |
Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
|
MX336726B
(es)
|
2010-09-27 |
2016-01-27 |
Abbott Gmbh & Co Kg |
Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
|
CA3152557A1
(en)
|
2010-10-29 |
2012-05-03 |
Abbvie Inc. |
Solid dispersions containing an apoptosis-inducing agent
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
WO2012059431A1
(en)
|
2010-11-01 |
2012-05-10 |
Abbott Gmbh & Co. Kg |
Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
|
WO2012059432A1
(en)
|
2010-11-01 |
2012-05-10 |
Abbott Gmbh & Co. Kg |
N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
|
CA2817093A1
(en)
|
2010-11-15 |
2012-05-24 |
Abbvie Inc. |
Nampt inhibitors
|
US9302989B2
(en)
|
2010-11-15 |
2016-04-05 |
Abbvie Inc. |
NAMPT and rock inhibitors
|
WO2012067822A1
(en)
|
2010-11-16 |
2012-05-24 |
Abbott Laboratories |
Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
|
WO2012067824A1
(en)
|
2010-11-16 |
2012-05-24 |
Abbott Laboratories |
Potassium channel modulators
|
KR101923364B1
(ko)
|
2010-11-23 |
2018-11-30 |
애브비 인코포레이티드 |
아폽토시스유도제의 염 및 결정형
|
CA2820618C
(en)
|
2010-11-23 |
2020-04-21 |
Steven Elmore |
Use of sulfonylbenzamide compounds in the treatment of systemic lupus erythematosus, lupus nephritis, or sjogren's syndrome
|
US9795601B2
(en)
*
|
2010-12-15 |
2017-10-24 |
Biovista, Inc. |
Compositions and methods for cancer treatment
|
US9090592B2
(en)
|
2010-12-30 |
2015-07-28 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
US8802693B1
(en)
|
2011-03-09 |
2014-08-12 |
Abbvie Inc. |
Azaadamantane derivatives and methods of use
|
US9012651B2
(en)
|
2011-03-24 |
2015-04-21 |
Abbvie Inc. |
TRPV3 modulators
|
CN103635458B
(zh)
|
2011-03-25 |
2016-10-19 |
艾伯维公司 |
Trpv1拮抗剂
|
US10457659B2
(en)
|
2011-04-29 |
2019-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for increasing proliferation of adult salivary stem cells
|
US9309200B2
(en)
|
2011-05-12 |
2016-04-12 |
AbbVie Deutschland GmbH & Co. KG |
Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US8859549B2
(en)
|
2011-05-13 |
2014-10-14 |
Abbvie, Inc. |
Potassium channel modulators
|
CA2844275A1
(en)
|
2011-08-05 |
2013-02-14 |
AbbVie Deutschland GmbH & Co. KG |
Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
|
TWI561521B
(en)
|
2011-10-14 |
2016-12-11 |
Abbvie Inc |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
TWI571466B
(zh)
|
2011-10-14 |
2017-02-21 |
艾伯維有限公司 |
用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
|
CA2853097A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Novel trpv3 modulators
|
US20130116241A1
(en)
|
2011-11-09 |
2013-05-09 |
Abbvie Inc. |
Novel inhibitor compounds of phosphodiesterase type 10a
|
WO2013072520A1
(en)
|
2011-11-18 |
2013-05-23 |
AbbVie Deutschland GmbH & Co. KG |
N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US8859584B2
(en)
|
2011-12-19 |
2014-10-14 |
Abbvie, Inc. |
TRPV1 antagonists
|
WO2013096226A1
(en)
|
2011-12-19 |
2013-06-27 |
Abbvie Inc. |
Trpv1 antagonists
|
US9365512B2
(en)
|
2012-02-13 |
2016-06-14 |
AbbVie Deutschland GmbH & Co. KG |
Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
|
WO2013149376A1
(en)
|
2012-04-02 |
2013-10-10 |
Abbott Laboratories |
Chemokine receptor antagonists
|
EP2838881B1
(en)
|
2012-04-20 |
2018-08-08 |
AbbVie Inc. |
Isoindolone derivatives
|
US9334264B2
(en)
|
2012-05-11 |
2016-05-10 |
Abbvie Inc. |
NAMPT inhibitors
|
JP2015516436A
(ja)
|
2012-05-11 |
2015-06-11 |
アッヴィ・インコーポレイテッド |
Nampt阻害薬
|
CN104583194A
(zh)
|
2012-05-11 |
2015-04-29 |
艾伯维公司 |
作为nampt抑制剂的哒嗪和吡啶衍生物
|
CA2873060A1
(en)
|
2012-05-11 |
2013-11-14 |
Abbvie Inc. |
Nampt inhibitors
|
US20130317055A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Neuronal nicotinic agonist and methods of use
|
US20130317054A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Neuronal nicotinic agonist and methods of use
|
MX2014015156A
(es)
|
2012-06-12 |
2015-08-06 |
Abbvie Inc |
Derivados de piridinona y piridazinona.
|
US8796328B2
(en)
|
2012-06-20 |
2014-08-05 |
Abbvie Inc. |
TRPV1 antagonists
|
US20140080813A1
(en)
|
2012-09-14 |
2014-03-20 |
AbbVie Deutschland GmbH & Co. KG |
Tricyclic quinoline and quinoxaline derivatives
|
CA2884548A1
(en)
|
2012-09-14 |
2014-03-20 |
AbbVie Deutschland GmbH & Co. KG |
Tricyclic quinoline and quinoxaline derivatives
|
WO2014160017A1
(en)
|
2013-03-13 |
2014-10-02 |
Abbvie Inc. |
Pyridine cdk9 kinase inhibitors
|
EP2970268A1
(en)
|
2013-03-13 |
2016-01-20 |
AbbVie Inc. |
Cdk9 kinase inhibitors
|
AU2014231567A1
(en)
|
2013-03-14 |
2015-10-01 |
Abbvie Inc. |
Pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors
|
US20140275082A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
WO2014140186A1
(en)
|
2013-03-14 |
2014-09-18 |
AbbVie Deutschland GmbH & Co. KG |
Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
|
TW201446763A
(zh)
|
2013-03-14 |
2014-12-16 |
Abbvie Inc |
吡咯并[2,3-b]吡啶cdk9激酶抑制劑
|
WO2014160185A2
(en)
|
2013-03-14 |
2014-10-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
|
AU2014230745A1
(en)
|
2013-03-14 |
2015-09-03 |
AbbVie Deutschland GmbH & Co. KG |
Novel inhibitor compounds of phosphodiesterase type 10A
|
BR112015023078A2
(pt)
|
2013-03-14 |
2017-07-18 |
Abbvie Inc |
inibidores de pirrolopirimindina cdk9 quinase
|
US9650334B2
(en)
|
2013-03-15 |
2017-05-16 |
Abbvie Inc. |
Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US9656955B2
(en)
|
2013-03-15 |
2017-05-23 |
Abbvie Inc. |
Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
KR20160062164A
(ko)
|
2013-10-17 |
2016-06-01 |
아비에 도이치란트 게엠베하 운트 콤파니 카게 |
아미노크로만, 아미노티오크로만 및 아미노-1,2,3,4-테트라하이드로퀴놀린 유도체, 이들을 포함하는 약제학적 조성물, 및 치료에서 이들의 용도
|
MX2016004934A
(es)
|
2013-10-17 |
2016-12-20 |
Abbvie Deutschland |
Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
|
US9840495B2
(en)
|
2013-12-20 |
2017-12-12 |
AbbVie Deutschland GmbH & Co. KG |
Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
|
US9328112B2
(en)
|
2014-02-06 |
2016-05-03 |
Abbvie Inc. |
Tetracyclic CDK9 kinase inhibitors
|
EP3143023B1
(en)
|
2014-05-15 |
2018-04-11 |
AbbVie Deutschland GmbH & Co. KG |
Oxindole compounds carrying a co-bound spiro substituent and use thereof for treating vasopressin-related diseases
|
US9617226B2
(en)
|
2014-09-05 |
2017-04-11 |
AbbVie Deutschland GmbH & Co. KG |
Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
|
US9550754B2
(en)
|
2014-09-11 |
2017-01-24 |
AbbVie Deutschland GmbH & Co. KG |
4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
|
CN104327004A
(zh)
*
|
2014-11-17 |
2015-02-04 |
重庆华邦制药有限公司 |
高纯度利奈唑胺氮氧化物的制备方法
|
US20180243298A1
(en)
|
2015-04-02 |
2018-08-30 |
Abbvie Inc. |
Trpv3 modulators
|
WO2017089458A1
(en)
|
2015-11-25 |
2017-06-01 |
AbbVie Deutschland GmbH & Co. KG |
Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders
|
DK3452484T3
(da)
|
2016-05-07 |
2023-09-25 |
Fochon Pharmaceuticals Ltd |
Visse protein-kinase-inhibitorer
|
EP3544965A4
(en)
|
2016-11-28 |
2020-05-20 |
Shanghai Fochon Pharmaceutical Co., Ltd. |
SULFOXIMIN, SULFONIMIDAMID, SULFONDIIMIN AND DIIMIDOSULFONAMID COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE
|
US9859219B1
(en)
|
2017-01-24 |
2018-01-02 |
International Business Machines Corporation |
Copper wiring structures with copper titanium encapsulation
|
US20200039930A1
(en)
|
2017-03-21 |
2020-02-06 |
AbbVie Deutschland GmbH & Co. KG |
Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical
|
CN110546151B
(zh)
|
2017-04-18 |
2023-04-28 |
重庆复创医药研究有限公司 |
凋亡诱导剂
|
AU2019233204B2
(en)
|
2018-03-14 |
2022-02-03 |
Fochon Biosciences, Ltd. |
Substituted (2-azabicyclo (3.1.0) hexan-2-yl) pyrazolo (1, 5-a) pyrimidine and imidazo (1, 2-b) pyridazine compounds as TRK kinases inhibitors
|
AU2019236892B2
(en)
|
2018-03-23 |
2023-12-14 |
Fochon Pharmaceuticals, Ltd. |
Deuterated compounds as ROCK inhibitors
|
WO2020234636A1
(en)
|
2019-05-17 |
2020-11-26 |
Cadila Healthcare Limited |
Novel compounds for the treatment of mammalian infections
|
US11608320B2
(en)
|
2020-02-02 |
2023-03-21 |
Kuwait University |
Oxazolidinone hydroxamic acid derivatives
|